ES2626610T3 - Bacterias de ácido láctico productoras del anti-TNF alfa para el tratamiento de la enfermedad inflamatoria intestinal - Google Patents

Bacterias de ácido láctico productoras del anti-TNF alfa para el tratamiento de la enfermedad inflamatoria intestinal Download PDF

Info

Publication number
ES2626610T3
ES2626610T3 ES06778386.0T ES06778386T ES2626610T3 ES 2626610 T3 ES2626610 T3 ES 2626610T3 ES 06778386 T ES06778386 T ES 06778386T ES 2626610 T3 ES2626610 T3 ES 2626610T3
Authority
ES
Spain
Prior art keywords
inflammatory bowel
bowel disease
treatment
lactic acid
acid bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06778386.0T
Other languages
English (en)
Inventor
Pieter Rottiers
Klaas Vandenbroucke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intrexon Actobiotics NV
Original Assignee
Intrexon Actobiotics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Actobiotics NV filed Critical Intrexon Actobiotics NV
Application granted granted Critical
Publication of ES2626610T3 publication Critical patent/ES2626610T3/es
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

El uso de un Lactococcus lactis productor de VHH anti-TNFa para la preparación de un medicamento para tratar la enfermedad inflamatoria intestinal (IBD), en la que se debe administrar una cantidad eficaz de dicho Lactococcus lactis productor de VHH anti-TNFa al tracto gastrointestina.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
ES06778386.0T 2005-08-30 2006-08-30 Bacterias de ácido láctico productoras del anti-TNF alfa para el tratamiento de la enfermedad inflamatoria intestinal Active ES2626610T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05107909 2005-08-30
EP05107909 2005-08-30
EP05111654 2005-12-02
EP05111654 2005-12-02
PCT/EP2006/065803 WO2007025977A2 (en) 2005-08-30 2006-08-30 Anti-tnf alpha producing lactic acid bacteria for the treatment of chronic enterocolitis

Publications (1)

Publication Number Publication Date
ES2626610T3 true ES2626610T3 (es) 2017-07-25

Family

ID=37335304

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06778386.0T Active ES2626610T3 (es) 2005-08-30 2006-08-30 Bacterias de ácido láctico productoras del anti-TNF alfa para el tratamiento de la enfermedad inflamatoria intestinal

Country Status (7)

Country Link
US (1) US9017662B2 (es)
EP (2) EP1948206B1 (es)
JP (1) JP5049973B2 (es)
AU (1) AU2006286563B2 (es)
CA (2) CA2619748C (es)
ES (1) ES2626610T3 (es)
WO (1) WO2007025977A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008147398A (ru) 2006-05-02 2010-06-10 Актогеникс Н.В. (Be) Доставка пептидов, связанных с ожирением, через кишечник посредством микроорганизмов
WO2008071751A1 (en) * 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
US8647626B2 (en) 2007-10-02 2014-02-11 Avaxia Biologics, Incorporated Compositions comprising TNF-specific antibodies for oral delivery
EP2244735A4 (en) * 2007-10-02 2011-02-23 Avaxia Biologics Inc ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
KR101593285B1 (ko) * 2008-10-29 2016-02-11 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
EP2343319A1 (en) 2010-01-07 2011-07-13 University of Ljubljana Genetically modified food grade microorganism for treatment of inflammatory bowel disease
CA2848471C (en) 2011-09-23 2021-11-16 Actogenix Nv Modified gram positive bacteria and uses thereof
DK2758512T3 (en) 2011-09-23 2018-07-23 Intrexon Actobiotics Nv MODIFIED GRAM POSITIVE BACTERIES AND APPLICATIONS THEREOF
EP3237622B1 (en) 2014-12-23 2021-02-24 Ilya Pharma AB Methods for wound healing
MX2017012662A (es) 2015-03-31 2018-05-11 Vhsquared Ltd Polipeptidos.
KR102789821B1 (ko) 2015-03-31 2025-04-02 소리소 파마슈티컬스 인크. 프로테아제-절단가능 링커를 갖는 펩티드 구조물
JP2018511346A (ja) 2015-03-31 2018-04-26 ブイエイチスクエアード リミテッド ポリペプチド
NO2768984T3 (es) 2015-11-12 2018-06-09
EP3512872A1 (en) 2016-09-13 2019-07-24 Intrexon Actobiotics NV Mucoadhesive microorganism
WO2018060453A1 (en) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
WO2020114616A1 (en) * 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
WO2020144164A1 (en) 2019-01-07 2020-07-16 Bactolife Aps Pathogen binding proteins
ES2974189T3 (es) * 2019-02-07 2024-06-26 Massachusetts Gen Hospital Carotenoides C50 para tratar o prevenir las náuseas
EP3986570A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Compositions
CN114514243B (zh) 2019-06-21 2025-01-24 索瑞索制药公司 多肽
EP3986571A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
CN110893194B (zh) * 2019-11-20 2023-03-14 内蒙古伊利实业集团股份有限公司 乳双歧杆菌bl-99在抑制肠道炎症方面的新应用
WO2023277778A1 (en) * 2021-06-29 2023-01-05 Milmed Unico Ab Yeast for the treatment of inflammation
JP2023139384A (ja) * 2022-03-22 2023-10-04 株式会社HanaVax ヒトノロウイルスｇｉｉ．２特異的抗体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
GB9521568D0 (en) 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
ATE259829T1 (de) * 1998-10-20 2004-03-15 Vlaams Interuniv Inst Biotech Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
FR2810337B1 (fr) * 2000-06-20 2002-09-13 Univ Clermont Auvergne Micro-organismes actifs dans l'environnement digestif
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
EP2284192A3 (en) * 2002-11-08 2011-07-20 Ablynx N.V. Camelidae antibodies for sublingual administration
EP1481681A1 (en) * 2003-05-30 2004-12-01 Claudio De Simone Lactic acid bacteria combination and compositions thereof

Also Published As

Publication number Publication date
EP1948206A2 (en) 2008-07-30
US9017662B2 (en) 2015-04-28
CA2925307C (en) 2019-12-03
JP5049973B2 (ja) 2012-10-17
WO2007025977A8 (en) 2008-12-11
AU2006286563A1 (en) 2007-03-08
WO2007025977A3 (en) 2007-06-07
CA2619748A1 (en) 2007-03-08
CA2619748C (en) 2016-06-14
JP2009506095A (ja) 2009-02-12
AU2006286563B2 (en) 2012-02-23
EP1948206B1 (en) 2017-03-01
EP3181141A1 (en) 2017-06-21
WO2007025977A2 (en) 2007-03-08
US20080274084A1 (en) 2008-11-06
CA2925307A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
ES2477882T3 (es) Probióticos, IgA secretora e infección
ES2611483T3 (es) Agente terapéutico para enfermedad inflamatoria intestinal
DK1978821T3 (da) Fremgangsmåde til at modificere tarmflora i dyr
ES2550059T3 (es) Método para usar una cepa de Bacillus subtilis para la profilaxis y el tratamiento de afecciones gastrointestinales
PT2131680E (pt) Probióticos para melhorar a microflora intestinal
EP3904502A3 (en) Compositions and methods
MX338247B (es) Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos.
CL2008000928A1 (es) Uso de bacterias probioticas de las especies lactobacillus rhamnosus, cepas atcc 53103 ó cgmcc 13724 para la fabaricacion de un medicamento o formula infantil que permite reducir el riesgo de que el infante desarrolle obesidad a lo largo de su vida.
CL2012001950A1 (es) Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño
ES2515168T3 (es) Detección y tratamiento de la esquizofrenia
RU2018121036A (ru) Комбинированная пре- и пробиотическая композиция
WO2007025977A8 (en) Anti-tnf alpha producing lactic acid bacteria for the treatment of chronic enterocolitis
MY148484A (en) Caspase imaging probes
ATE460940T1 (de) Eisen(iii) komplex-verbindungen zur oralen behandlung von eisenmangel bei patienten mit chronischen entzündlichen darmerkrankungen
MX338684B (es) Prevencion y tratamiento de infeccion gastrointestinal en mamiferos.
MX2010001381A (es) Genes y proteinas de brachyspira hyodysenteriae y usos de los mismos.
NZ600700A (en) Composition containing bacterium capable of producing propionic acid bacterium, and use thereof
ES2525931T3 (es) Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal
ES2544780T3 (es) Metadoxina para su uso como inhibidor de fibrosis hepática
PE20130308A1 (es) Metodos para tratar infecciones bacterianas recurrentes
RU2010125576A (ru) Способ получения аутопробиотика, содержащего живые бифидобактерии и лактобациллы
EP2255675A3 (fr) Procédé d'obtention de foie gras comprenant l'administration de bactéries probiotiques
UY33218A (es) Agente precursor de iodo para la obtencion de imagenes pet de placas amiloides
RU2013108544A (ru) Способ диагностики метаплазии пищевода и желудка
Xu Esophageal ulcer: case report